Related Experiment Video
Updated: Feb 20, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
A Retrospective Study on Infusion-Related Reactions to Rituximab in a Heterogeneous Pediatric Population
Clément Legeay1, Henrique Bittencourt1, Elie Haddad1
1Department of Pharmacy (CL, RT), CHU Ste Justine, University of Montreal, Montréal, Quebec, Canada; Department of Oncology-Haematology (HB), CHU Ste Justine, University of Montreal, Montréal, Quebec, Canada; Department of Pediatrics, Department of Microbiology, Infectiology and Immunology (EH), University of Montreal, Montreal, Quebec, Canada; Department of Pharmacy (JSR), CHU d'Angers, University of Angers, Angers, France; Department of Medical Information (VTS), CHU d'Angers, University of Angers, Angers, France.
Objectives:
To assess risks and outcomes of infusion-related reactions to rituximab in a heterogeneous pediatric population.
Methods:
All patients who received rituximab between July 2010 and July 2012 were retrieved from the pharmacy software and included for analysis. Data were collected according to 4 categories: demographic data, infusion data, infusion-related reactions, and biological data considered as risk factors (i.e., absolute lymphocyte count, lactate dehydrogenase levels).
Results:
Sixty-seven patients treated for a total of 17 different indications were included. A total of 282 rituximab infusions were administered. Forty-three, mostly grade 1 or 2, infusion-related reactions occurred in 30 patients. Reactions occurred in 39.2% "first-dose" infusions, but this rate dropped drastically to 2.7% in subsequent doses. In multivariate analysis, high absolute lymphocyte count was the only risk factor for infusion-related reaction (OR = 1.03; 95% CI: 1.01-1.06; p = 0.014).
Conclusions:
Rituximab infusion-related reactions in a heterogeneous pediatric population were frequent on first infusion, but rare in subsequent ones. Overall, these reactions were mild and manageable through pharmacological treatment. Patients with an elevated absolute lymphocyte count before infusion were at greater risk for an infusion-related reaction.
More Related Videos
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug Dosing: Infants and Children
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
